Cansino Biologics Inc

Overnight in the US market, mRNA vaccine maker Moderna saw its share price jump 14.36 percent, lifting vaccine sectors in both A-shares and Hong Kong stocks. On August 26, A-share CanSino Biologics hit the daily limit up, Wantai Biological Pharmacy also hit the daily limit up, while Zhifei Biological Products and Walvax Biotechnology rose more than 6 percent. In Hong Kong, CanSino Biologics surged more than 20 percent. Earlier, Moderna and Merck jointly announced that their personalised mRNA cancer vaccine met the primary endpoint in a Phase III clinical trial, making it the world's first personalised neoantigen therapy to deliver a positive result. Chinese companies such as CanSino Biologics have already announced plans to develop personalised mRNA tumour vaccines. However, the vaccine currently targets only melanoma, and its production cost is relatively high, so it is still some distance from being widely available to ordinary patients. Industry insiders estimate that its cost is lower than cell therapy but higher than ordinary antibody drugs, and China's mRNA cancer vaccine development remains in the early clinical stage.

On the morning of August 26, CanSino Biologics hit its 20 percent daily price limit just 48 seconds after the market opened, boosting activity across the pharmaceutical and biotech sector. After the close on the previous day, CanSino announced that its subsidiary CanSino Shanghai had signed a strategic cooperation framework agreement with Dephios Bio to co-develop a personalized therapeutic mRNA cancer vaccine. The two sides will combine their respective strengths in mRNA vaccine technology and tumor neoantigen discovery and design to jointly advance the vaccine's development and commercialization. The collaboration is global in scope and focuses on gastrointestinal solid tumors and rare tumor treatment. A representative from CanSino's securities department said the vaccine is still in the early research stage and commercialization will take a long time. A research note from Sinolink Securities pointed out that China's mRNA industry landscape has taken shape, but therapeutic mRNA products overall remain in early clinical stages.

On the morning of August 26, China's three major A-share indexes were mixed, while the pharmaceutical and biotech sector was active, with CanSino Biologics surging by the 20 percent daily limit. In terms of news, CanSino Biologics announced that its subsidiary CanSino Shanghai and Depushi Hangzhou Biotechnology Company Limited signed a strategic cooperation framework agreement for the joint development of mRNA personalized therapeutic cancer vaccines. The two sides will jointly advance the research, development, and commercialization of mRNA personalized therapeutic cancer vaccines, focusing on gastrointestinal solid tumors and rare tumor treatment areas. In addition, Hansen Pharmaceutical rose by the daily limit for the sixth consecutive day, while Qianjin Pharmaceutical, Yibai Pharmaceutical, and Wantai Biological Pharmacy also hit their daily limits. In the Hong Kong market, stocks fluctuated higher, with the Hang Seng Tech Index rising more than 1 percent, and XPeng, NIO, and Alibaba among the top gainers.

Moderna and Merck announced preliminary positive results from the Phase III clinical trial of their mRNA personalized cancer vaccine, intismeran autogene, igniting the A-share pharmaceutical sector. On the morning of August 20, multiple vaccine stocks including Baike Biotech, Walvax Biotechnology, CanSino Biologics, Kanghua Biologics, Laimei Pharmaceutical, and Novoprotein hit the 20% daily limit, while Hong Kong-listed CanSino Biologics and Everest Medicines surged over 50% intraday. The vaccine, combined with Keytruda, was used as adjuvant therapy in more than 1,100 high-risk melanoma patients after complete surgical resection, achieving key endpoints of recurrence-free survival and reduced risk of distant metastasis. Following the announcement, Moderna's stock price soared nearly 180%, while Merck's rose over 12%.

CanSino Biologics announced that it has received the Drug Registration Certificate from the National Medical Products Administration for its adsorbed tetanus vaccine. The vaccine is mainly used for the prevention of tetanus in non-neonates, and is produced using animal-free culture media. Phase III clinical data showed immunogenicity superior to the control vaccine. The company has entered into an exclusive commercialization cooperation agreement with Grand Life Sciences for the vaccine, authorizing it to provide exclusive promotion services in Greater China. The launch of this product will enrich the company's commercial product portfolio, expand its presence in the adult vaccine market, and have a positive impact on its performance.

CanSino Biologics' self-developed adsorbed acellular DTP combined vaccine for infants, Pancocin, has received the Biologics Batch Release Certificate for its first batch, officially entering the market supply stage. On August 13, the bioproducts sector rose 3.01% intraday, with Novoprotein up 13.99%, Staidson up 11.12%, ACROBiosystems up 9.03%, OPM Biosciences up 8.78%, and Junshi Biosciences up 8.08%. Huayuan Securities research notes that the biologics market continues to expand, expected to reach 904.8 billion yuan by 2029, with a compound annual growth rate of 11.28% from 2020 to 2029, directly driving demand for upstream core consumables such as cell culture media. The Chinese market is expected to reach 683 million US dollars by 2029, with a compound annual growth rate of 14.00%, and the trend toward domestic self-reliance is clear.

CanSino announced that the supplementary drug application for its ACYW135 meningococcal polysaccharide conjugate vaccine (CRM197 carrier), Menhycia®, has been accepted by the National Medical Products Administration. The application seeks to expand the indicated age range from children aged 3 months to 6 years to individuals aged 3 months to 17 years. Menhycia® is China's first quadrivalent meningococcal conjugate vaccine, approved for marketing in December 2021, and its indicated age range was expanded to children aged 3 months to 6 years in February 2026. The vaccine has filled a gap in the domestic high-end vaccine market, with its market share continuing to rise. This supplementary application still requires an approval notice, and its acceptance will not have a significant impact on the company's current performance.

A new report from DelveInsight reveals that more than 28 companies are actively developing over 30 pipeline drugs for tuberculosis. Key players include Biofabri, Otsuka Pharmaceutical, GlaxoSmithKline, Archivel Farma, BioNTech, CanSino Biologics Inc., Medincell, and others, with promising therapies such as MTBVAC, Quabodepistat, GSK3036656, RUTI, BNT164, and Ad5-105K in various clinical stages. Approximately four-plus drugs are in late-stage development, and notable mechanisms of action include leucyl-tRNA synthetase inhibitors, immunostimulants, and DprE1 protein inhibitors. The report also highlights recent milestones, including the first patient dosed in a Phase IIb trial of alpibectir-ethionamide in March 2026 and the initiation of a new cohort in the IMAGINE trial of MTBVAC in February 2026.

CanSino Biologics stated in its investor relations record released on July 3 that the infant three-component DTP vaccine DT3cP, PanKangXin, developed by the company is expected to receive its first batch release in July. PanKangXin is the first domestically approved component pertussis vaccine, containing three antigens—PT, FHA, and PRN—offering more comprehensive protection. It has already gained market access in several provinces, and batch release and local tender access work is proceeding in an orderly manner. This year, the company will focus on academic promotion and market education around the product's advantages, gradually opening up the infant pertussis immunization market. In addition, the 13-valent pneumococcal conjugate vaccine, YouPeiXin, has gained access in over 25 provinces, autonomous regions, and municipalities nationwide, and vaccination has commenced in multiple locations, currently in the sales ramp-up phase. The company is also advancing early-stage research on mRNA therapeutic vaccines, having developed a proprietary three-component lipid nanoparticle delivery system, and has already out-licensed it through an agreement with Panru Bio.